Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
Status:
Completed
Trial end date:
2016-10-26
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy, safety, and tolerability of
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose
combination (FDC) in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) coinfected
adults.
Participants will be enrolled into two cohorts:
- Cohort 1: HIV/HBV coinfected adults who are HIV treatment-naive and HBV treatment-naive
- Cohort 2: HIV/HBV coinfected adults who are HIV-suppressed
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination